| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner | Director, 10% Owner
5 companies
Invus Public Equities, L.P. last filed a Form 4 in December 2024, as Director, 10% Owner at LXRX. The filings on record cover 5 companies. From November 2017 to December 2024, the filings on record show 22 open-market purchases and 8 sales.
Our model assigns Invus Public Equities, L.P. a strong insider score of 78/100, based on 26 past trades. Over a 12-month horizon, 80.8% of those trades were profitable, with an average 12-month return of +40.5%.
At the last filing, the largest reported position was 9,250,005 shares of SRRK. Net of sales, the SRRK filings show accumulation of 499,971 shares.
Shares as reported in the last Form 4 for each company; the most recent is from December 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 28, 2018 | LXRX Lexicon Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 182,838 | $12.51 | $2,287,376.72 | +5.5% | |
| Jun 25, 2018 | LXRX Lexicon Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 253,725 | $12.99 | $3,295,173.13 | +8.2% | |
| Jun 21, 2018 | LXRX Lexicon Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 72,973 | $13.29 | $970,045.19 | +2.4% | |
| Jun 18, 2018 | LXRX Lexicon Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 45,784 | $12.98 | $594,398.91 | +1.5% | |
| Jun 12, 2018 | LXRX Lexicon Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 235,396 | $12.80 | $3,014,123.06 | +8.6% | |
| Jun 7, 2018 | LXRX Lexicon Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 325,639 | $12.58 | $4,095,065.19 | +13.6% | |
| Jun 4, 2018 | LXRX Lexicon Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 416,481 | $12.01 | $5,002,666.67 | +21.0% | |
| May 30, 2018 | LXRX Lexicon Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 433,378 | $9.94 | $4,306,418.18 | +28.0% | |
| Nov 17, 2017 | LXRX Lexicon Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 180,727 | $10.11 | $1,826,895.85 | +13.2% | |
| Nov 14, 2017 | LXRX Lexicon Pharmaceuticals, Inc. | Director, 10% Owner | Buy | 575,946 | $9.64 | $5,554,165.52 | +72.6% |